Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage biotechs. Local industry leaders say that could change ...
The fund aims to build a portfolio of 20-25 companies that address gaps in services and products across pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback